These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 11957988

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Sgroi DC, Haber DA, Ryan PD, Ma XJ, Erlander MG.
    Cancer Cell; 2004 Nov; 6(5):445. PubMed ID: 15542428
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Basic Consensus on endocrinotherapy for breast cancer].
    Jiang ZF, Xu BH, Song ST.
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):238-9. PubMed ID: 16875616
    [No Abstract] [Full Text] [Related]

  • 6. Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
    Jansen MP, Foekens JA, Klijn JG, Berns EM.
    J Natl Cancer Inst; 2005 Dec 21; 97(24):1851-2; author reply 1852-3. PubMed ID: 16368948
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Estrogen and progesterone receptors in breast cancer].
    Sonoo H.
    Nihon Rinsho; 2000 Apr 21; 58 Suppl():146-53. PubMed ID: 11025988
    [No Abstract] [Full Text] [Related]

  • 10. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
    Muss HB, Bunn JY, Crocker A, Plaut K, Koh J, Heintz N, Rincon M, Weaver DL, Tam D, Beatty B, Kaufman P, Donovan M, Verbel D, Weiss L.
    Breast J; 2007 Apr 21; 13(4):337-45. PubMed ID: 17593037
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients.
    Blackman SB, Lash TL, Fink AK, Ganz PA, Silliman RA.
    Cancer; 2002 Dec 15; 95(12):2465-72. PubMed ID: 12467058
    [Abstract] [Full Text] [Related]

  • 15. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH, Hayes DF.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract] [Full Text] [Related]

  • 16. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB, Feuer EJ, Harlan LC, Abrams J.
    J Natl Cancer Inst Monogr; 2006 Sep 20; (36):7-15. PubMed ID: 17032888
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
    Oncology (Williston Park); 2005 Mar 20; 19(3):277, 360. PubMed ID: 15828547
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic factors for breast cancer and their use in the clinical setting.
    Kapoor A, Vogel VG.
    Expert Rev Anticancer Ther; 2005 Apr 20; 5(2):269-81. PubMed ID: 15877524
    [Abstract] [Full Text] [Related]

  • 20. Tumoristatic action of tamoxifen: experimental evidence for clinical application in stage I and II breast cancer.
    Jordan VC.
    J Chemother; 1989 Jul 20; 1(4 Suppl):1144-7. PubMed ID: 16312810
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.